Flash e-reader

 Go to e-reader chapter








Table 13.6b

Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009

Recipients with Heart-Lung Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF CyA+ Aza Tac+ Aza Other
Functioning Graft with Immunosuppression Info at Discharge 1 9 9 78 14 9 5 125
% of All Regimens 0.8% 7.2% 7.2% 62.4% 11.2% 7.2% 4.0% 100.0%
Induction Drug 0.0% 11.1% 22.2% 14.1% 21.4% 0.0% 40.0% 15.2%
Atgam/NRATG/NRATS
OKT3 0.0% 11.1% 0.0% 1.3% 7.1% 0.0% 0.0% 2.4%
Thymoglobulin 0.0% 0.0% 0.0% 5.1% 0.0% 0.0% 0.0% 3.2%
Zenapax 0.0% 22.2% 11.1% 21.8% 28.6% 11.1% 80.0% 23.2%
Simulect 0.0% 11.1% 55.6% 7.7% 21.4% 44.4% 80.0% 18.4%
Campath 0.0% 11.1% 0.0% 19.2% 0.0% 0.0% 60.0% 15.2%
No Induction Drugs Recorded 100.0% 55.6% 11.1% 33.3% 21.4% 44.4% 0.0% 32.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.